Cramer's 'Mad Money' Recap: Checking My List
NEW YORK ( TheStreet) -- April is the most bountiful month of the year when it comes to the stock market, Jim Cramer told his "Mad Money" TV show viewers Monday. That's why Cramer is pushing the skeptics aside and reviewing his "Do Something" list of stocks that are taking charge of their own destinies.
Cramer first debuted his "Do Something" list on Nov. 29 and since then the 10 stocks have risen 23.9%, far more than the market's 10.2% rise.
Leading the group is Hess
Also on the list: Johnson & Johnson
Finally, there's Bed Bath & Beyond
Cramer said he'd still be a buyer of all these names except, perhaps, Hess, which has lost some luster because it has already unlocked much of its value.
The future of drug stocks isn't with Big Pharma, Cramer told viewers, it's with smaller biotech names. That's why Cramer continued his in-depth look at the biotech sector by taking a peek at some of the smaller, more speculative companies that treat orphan diseases. He reminded viewers that while orphan drugs often treat fewer than 200,000 patients, thanks to Food and Drug Administration protections companies can charge upwards of $200,000 per year per patient for some of these cutting-edge therapies.
Among his favorites in the group are Alexion Pharmaceuticals